Suven Pharma Q2 results: Net profit declines 5.3% YoY to Rs 74.72 crore
Suven Pharmaceuticals Ltd had reported a 12.2 percent year-on-year (YoY) rise in net profit at Rs 120.6 crore for the first quarter that ended June 30, 202309-11-2023
09-11-2023
Suven Pharmaceuticals Ltd - 543064 - Closure Of Register Of Members For The Purpose Of 5Th Annual General Meeting Of The Company
Closure of Register of Members for the purpose of 5th Annual General Meeting of the Company09-11-2023
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed investor presentation09-11-2023
Suven Pharmaceuticals Ltd - 543064 - Un-Audited Standalone And Consolidated Financial Results Prepared Under Ind AS For The Quarter And Half Year Ended September 30, 2023
Un- Audited Standalone and consolidated FInancial Results prepared under INA AS for quarter and half year ended September 30, 202309-11-2023
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Thursday, November 09, 2023 at 06:00 P.M IST to discuss the Un-audited Financial Results for the Q2 & H1 FY24, to be declared on November 09, 2023.02-11-2023
Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Thursday, The 09Th November, 2023 - Reg
Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 ,inter alia, to consider and approve the Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the second quarter and half-year ended September 30, 2023 and other matters.02-11-2023
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund & PACs23-10-2023
Suven Pharmaceuticals Ltd - 543064 - Updates on Open Offer
Kotak Mahindra Capital Company Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Post-Offer Advertisement in accordance with Regulation 18(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended, and Corrigendum to the Detailed Public Statement for the attention of the public shareholders of Suven Pharmaceuticals Ltd ("Target Company").19-10-2023
Suven Pharmaceuticals Ltd - 543064 - Submission Of Recommendations Of The Committee Of Independent Directors Under Regulation 26(7) Of The SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011.
Pursuant to Regulation 26(7) of the SEBi (SAST) Regulations, 2011, recommendations given by the Independent Directors Committee at its meeting held on October 16, 2023 to the public shareholders on the offer price of the open offer as appeared today October 17, 2023 in the newspapers. The Copy of advertisement in newspaper are enclosed.17-10-2023
Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issuance of Letter of Confirmation in lieu of Duplicate Share Certificate11-10-2023